Prof. Dr. Turgay Çelikel
OncologyVerified
- 47+years exp.
English · Turkish
FromPrice on request
Free quote
60 seconds · no obligationView Profile
Oncology
Acute Lymphoblastic Leukemia Treatment in Turkey
Acute lymphoblastic leukaemia is a rapid-progressing blood cancer originating from immature white blood cells known as lymphoblasts. Although it is the most common paediatric cancer, it also occurs in adults, prompting medical attention due to anaemia, persistent infections, unusual bleeding, and fatigue. Specific clinical protocols and treatment options depend on an urgent, in-depth specialist assessment. Compare hospitals in Turkey that treat Acute Lymphoblastic Leukemia and get a free review of your medical records.
- Price from
- Price on request
- Clinics
- 2
Verified surgeons for Acute Lymphoblastic Leukemia
1 doctor Compare doctors, ratings and prices — ask any of them for a free quote.
About Acute Lymphoblastic Leukemia
Acute lymphoblastic leukaemia is a rapid-progressing blood cancer originating from immature white blood cells known as lymphoblasts. Although it is the most common paediatric cancer, it also occurs in adults, prompting medical attention due to anaemia, persistent infections, unusual bleeding, and fatigue. Specific clinical protocols and treatment options depend on an urgent, in-depth specialist assessment.
Specialty: Oncology
Best Clinics for Acute Lymphoblastic Leukemia Treatment in Turkey
Frequently asked questions
The cost of treating Acute Lymphoblastic Leukemia depends on the diagnosis and the treatment chosen. Doctors first review your medical records — free of charge — and you then receive an itemised quote.
Acute Lymphoblastic Leukemia is treated by Oncology specialists. 2 clinics in Turkey on our platform offer this treatment.
What Acute Lymphoblastic Leukaemia Is and Typical Symptoms
Acute lymphoblastic leukaemia (ALL) is a rapidly progressing blood and bone marrow disorder. In ALL, genetic alterations cause the marrow to overproduce immature white blood cells called lymphoblasts. These abnormal cells multiply rapidly, crowding out healthy red blood cells, normal leukocytes, and platelets. While ALL is the most common childhood blood cancer, it also occurs in adults, often carrying distinct biological features.
Symptoms develop quickly as healthy blood cell production fails. Common clinical signs include:
- Fatigue and pallor: Driven by anaemia, causing breathlessness, dizziness, and persistent exhaustion.
- Recurrent infections: Caused by neutropenia, presenting as persistent fevers, chills, or mouth sores.
- Unusual bleeding or bruising: Due to low platelets (thrombocytopenia), causing frequent nosebleeds, bleeding gums, or petechiae (tiny purple skin spots).
- Bone and joint discomfort: Resulting from blast cell accumulation inside the marrow.
- Swollen lymph nodes and abdominal fullness: Caused by blast infiltration into the spleen, liver, or lymph nodes.
Diagnostic Evaluation and Records to Bring
Because ALL advances rapidly, prompt and precise diagnostic staging is vital. When presenting to a hospital in Turkey, haematologists conduct comprehensive tests to confirm the subtype (B-cell or T-cell lineage) and establish risk categories.
Standard hospital diagnostics include:
- Full blood count and blood smear: Evaluates cytopenias and detects circulating blast cells.
- Bone marrow aspiration and biopsy: Samples pelvic marrow to quantify blast percentages and evaluate cellular morphology.
- Flow cytometry and immunophenotyping: Profiles cell-surface markers to distinguish between B-cell and T-cell ALL.
- Cytogenetic and molecular testing: Detects genetic abnormalities, including the Philadelphia chromosome (BCR-ABL1), which directly guides therapy.
- Lumbar puncture: Tests cerebrospinal fluid for central nervous system leukaemia.
- Baseline organ assessment: Echocardiograms, renal function tests, and chest imaging evaluate physical fitness before systemic therapy.
Patients should bring comprehensive documentation: recent blood test results, bone marrow biopsy reports, pathology tissue slides or blocks, flow cytometry reports, and previous transfusion logs. Having medical records translated into English prevents clinical delays.
Treatment Options and Clinical Protocols
Treatment for ALL aims to clear leukaemia cells, restore normal marrow function, and prevent relapse. Medical teams in specialised oncology departments adapt protocols based on age, lineage, and genetic markers. For children and adolescents, joint management with paediatrics units ensures accurate dosing.
| Option | Typically used when | Things to know |
|---|---|---|
| Induction Chemotherapy | First phase for newly diagnosed ALL to achieve remission. | Requires multi-week hospitalisation due to severe neutropenia and infection risks. |
| Consolidation Therapy | Follows successful remission to eliminate residual blast cells. | Involves cyclical systemic chemotherapy combined with intrathecal injections to protect the central nervous system. |
| Targeted Therapy (TKIs) | Philadelphia chromosome-positive (Ph+) ALL alongside chemotherapy. | Oral medications that block the abnormal BCR-ABL tyrosine kinase protein. |
| Stem Cell Transplant | High-risk cytogenetics, poor initial response, or relapse. | Replaces unhealthy marrow with matched donor stem cells; requires extensive pre-transplant conditioning. |
| Maintenance Therapy | Final long-term phase after consolidation. | Lower-dose oral and outpatient medications taken over two to three years. |
Treatment plans are individualised. The attending haematologist determines all protocols after reviewing baseline check-ups and diagnostics. Post-chemotherapy physical recovery may involve specialised rehabilitation, while psychiatry and addiction services provide emotional and psychological support during long therapeutic cycles.
Planning Your Treatment and Stay in Turkey
Undergoing leukaemia treatment abroad requires structured logistical and clinical planning. Before travelling to Turkey, patients should arrange an advance medical record review with the treating haematology team. This step confirms immediate bed availability in an isolated or positive-pressure haematology ward.
Initial induction therapy typically requires an in-country stay of six to eight weeks. During this critical window, marrow suppression leaves patients vulnerable to opportunistic infections, requiring frequent blood component transfusions and strict barrier nursing. Travel back home is only possible once the treating doctor confirms absolute neutrophil and platelet counts have recovered to safe levels for flight. Subsequent maintenance phases can often be continued locally in the patient's home country under haematologist supervision.
Travel Precautions and When Urgent Local Care Is Required
Because ALL causes severe immunosuppression and bleeding risks, travelling without medical clearance is unsafe. Cabin air pressure and exposure to infections on commercial flights can trigger life-threatening complications if blood counts are depleted.
Patients should seek urgent emergency care at the nearest local hospital rather than attempting to travel if they develop any of these warning signs:
- Febrile neutropenia: A temperature of 38.0°C (100.4°F) or above requires immediate emergency evaluation and intravenous antibiotics within one hour.
- Severe bleeding: Uncontrolled epistaxis, coughing or vomiting blood, black tarry stools, or rapidly spreading skin petechiae.
- Acute breathlessness: Sudden chest tightness or shortness of breath, indicating possible pulmonary infection, severe anaemia, or cardiac strain.
- Neurological symptoms: Severe new headaches, vision changes, confusion, or seizures, which may indicate intracranial haemorrhage or leukemic involvement.
Frequently asked questions
Induction therapy usually lasts between four and six weeks. During this initial stage, intensive combination chemotherapy is given to clear blast cells from the bone marrow and peripheral blood. Patients generally remain in a protected hospital room throughout this phase because blood counts drop significantly, requiring intravenous antibiotics, supportive transfusions, and regular blood monitoring before remission can be assessed.
B-cell and T-cell ALL originate from different early lymphocyte lineages in the bone marrow or thymus. B-cell ALL is the most frequent form, often showing specific genetic alterations like the Philadelphia chromosome. T-cell ALL tends to occur more in adolescents and young adults, sometimes presenting with enlarged chest lymph nodes. Treatment regimens differ in chemotherapy drug combinations and targeted therapy options.
Acute lymphoblastic leukaemia cells have a known tendency to enter the central nervous system, crossing into the fluid surrounding the brain and spinal cord. A lumbar puncture samples cerebrospinal fluid to detect any microscopic blast cells. It also allows haematologists to administer prophylactic or therapeutic chemotherapy directly into the spinal fluid, preventing or treating leukemic involvement that standard intravenous medications cannot easily reach.
An allogeneic stem cell transplant is typically considered for patients with high-risk genetic features, those who do not achieve complete remission after initial induction, or individuals experiencing disease relapse. The decision depends on biological risk stratification, minimal residual disease (MRD) test results, the patient's general fitness, and the availability of a matched related or unrelated donor identified through human leukocyte antigen typing.
Travel between intensive cycles depends entirely on marrow recovery and absolute neutrophil and platelet levels. International travel during severe cytopenia is not recommended due to flight-related hypoxia and infection hazards. If counts have recovered adequately and the clinical team provides written clearance, short visits home may be feasible before the next consolidation block, though urgent local hospital access remains essential.